In agreement with studies that point to the complex regulation of oncogenic signaling in GBM [29], we observed that EGFR targetting fails to robustly inhibit ERK1/2 signaling, even in a context of genomic amplification of this receptor. This evidence concerns the gene MAPK3 and glioblastoma.